Tumor index can identify breast cancer patients’ drug response

Researchers at The Hong Kong Polytechnic University (PolyU) have developed an imaging biomarker, the Tumour Heterogeneity Index (THI), which enables noninvasive assessment of breast cancer patients' response to AKT inhibitors before treatment, helping clinicians identify patients most likely to benefit from therapy. The study found that patients with a high THI achieved an estimated pathological complete response (pCR) rate of 56.1%, significantly higher than that of patients with a low THI. The technology could help patients receive the most appropriate treatment at an earlier stage, reduce unnecessary side effects and enable clinicians to better tailor treatment strategies to individual patients.

Clot removal days after a stroke could help more patients recover, but the procedure is not without risks

After a person suffers a stroke, the clock starts ticking for doctors. Every minute that blood flow to the brain remains blocked, more brain tissue risks permanent damage or death. One way to restore circulation is through endovascular thrombectomy, a minimally invasive procedure that can physically remove the clot, restore blood flow and significantly reduce the risk of long-term disability or death. Such mechanical thrombectomy procedures are a standard emergency treatment within the first 24 hours of an acute ischemic stroke.

Newly discovered pathway fuels production of cancer-driving proteins

A previously unknown mechanism helps cancer cells selectively produce proteins that drive tumor growth—such as KRAS—in common cancers, according to new research from The University of Texas MD Anderson Cancer Center. The findings reveal that targeting a specific enzyme may improve responses to targeted therapies and help overcome treatment resistance.